Wendy's Rejects $1.4 Billion Takeover Bid From Nelson Peltz's Trian

Wendy's has rejected a $1.4 billion takeover offer from an investor group led by Nelson Peltz's Trian Fund Management, calling the bid too cheap for a chain mid-way through a turnaround.

The group offered $7.35 per share in cash on Oct. 28 to take the struggling burger chain private. Beyond Trian, the consortium included investment firms BlueFive Capital and Sixth Street Partners, plus Flynn Group, one of Wendy's largest franchisees.

The company announced its decision Thursday, backed by a committee of independent directors. Wendy's formed that committee in February to assess any potential bid from Trian after the firm made a regulatory filing. The committee concluded the proposal "substantially undervalues" Wendy's and ignores potential gains from the chain's ongoing turnaround strategy, the company said in a press release.

What does the rejection change for shareholders?

The board made its reasoning personal as well as financial. "Our confidence rests firmly in [CEO] Bob Wright's proven track record of seasoned industry leadership, including restaurant business turnarounds," Art Winkleblack, Wendy's board chair and a member of the independent committee, said in a statement.

The math explains the board's frustration. The stock has lost roughly 60% of its value over the past three years — that's about one-fifth of shareholder equity gone annually, on average — and the takeover talk had recently lifted the shares. After Thursday's rejection, the stock fell less than 1% in morning trading.

Trian declined to comment on Wendy's decision.

A poison pill, and a standstill offer that went nowhere

To stave off a hostile takeover, Wendy's adopted a shareholder rights plan — commonly called a poison pill — with a one-year duration, effective as of Wednesday. The move didn't come out of nowhere. Wendy's said it had offered the Trian-led group a standstill agreement that would have paused additional share purchases, and the investors rejected it. That refusal, the company added, contributed to its decision to trigger the pill.

Peltz and Wendy's: a two-decade entanglement

The rejection is the latest chapter in a saga between Peltz and the burger chain that dates back more than two decades, to an activist campaign he led. A Peltz firm has even owned Wendy's before. In 2008, his company Triarc, which also owned Arby's, bought Wendy's in a $2.3 billion deal. Triarc later sold Arby's, returning Wendy's to stand-alone status.

The ties run deeper than history. In 2024, Wendy's named Peltz chairman emeritus after he spent 17 years on the company's board. Trian executive Peter May and Peltz's son, Bradley, still sit on the board — meaning the bidder's people remain inside the house they're trying to buy.

Same-store sales fall for a seventh straight quarter

The corporate drama landed on the same day as Wendy's third-quarter results. Same-store sales declined for the seventh consecutive quarter — nearly two years of uninterrupted erosion in the chain's core metric. The top line wasn't the whole story, though: quarterly earnings and revenue both topped Wall Street's expectations.

That split — improving profitability against shrinking traffic — is exactly the tension behind the takeover fight. Trian sees a struggling asset; the board sees a turnaround with gains the $7.35 offer doesn't capture.

Wendy's isn't alone in drawing activist fire. Applebee's owner Dine Brands recently adopted its own poison pill to block a takeover bid from investment firms Arkhouse Management and Cobblers Cove Capital.

With the pill expiring in a year, the Trian group's next move — a raised bid, a proxy fight, or a walk-away — will set the price of independence for a chain whose board has now publicly bet on Bob Wright's turnaround over a cash exit.